HCFC1R1 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human ovarian carcinoma cell line A2780. This product provides a genetically disrupted pool of cells lacking functional HCFC1R1 expression, enabling loss-of-function studies. The polyclonal format captures a range of editing events across the population, offering a robust model for functional genomics. As a polyclonal knockout, it avoids clonal artifacts and represents a heterogeneous knockout response typical of CRISPR-mediated gene disruption.
The A2780 cell line is a human ovarian endometrioid adenocarcinoma line established from an untreated patient and is well-characterized for its cisplatin sensitivity. It is a widely utilized model for ovarian cancer research, particularly for studying drug responses and signaling pathways that drive tumorigenesis. Its epithelial origin and reproducible growth properties make it suitable for investigating proliferation, migration, and invasion in ovarian cancer. The A2780 background is a cornerstone in cancer biology for evaluating molecular mechanisms and therapeutic interventions.
HCFC1R1, also known as HPIP, functions as a scaffold protein that bridges the transcription factors PBX1 and HCFC1, modulating transcriptional complexes. It activates PI3K/AKT signaling to drive cell proliferation and migration. Upstream, HCFC1R1 is regulated by ER??, growth factors such as EGF and IGF, and the transcription factor STAT3. Downstream, it promotes AKT phosphorylation, leading to upregulation of Cyclin D1, MYC, and matrix metalloproteinases (MMPs). Through these interactions, HCFC1R1 integrates signals from growth factors and steroid hormones to control gene expression programs that enhance tumor progression.
In the A2780 ovarian cancer context, disruption of HCFC1R1 provides a precise tool to dissect its role in oncogenic signaling. Loss of HCFC1R1 impairs PI3K/AKT pathway activation, potentially reducing cell proliferation, migration, and invasion. This model allows examination of how HCFC1R1-dependent transcriptional regulation affects tumor cell behavior. The A2780 background is particularly relevant given its estrogen receptor positivity and sensitivity to cisplatin, enabling investigations into endocrine therapy cross-talk and chemoresistance mechanisms.
Researchers can employ these polyclonal knockout cells in a variety of assays to probe ovarian cancer biology. Representative applications include Western blotting for phosphorylated AKT to assess pathway activity, MTS cell proliferation assays to quantify growth effects, Transwell migration/invasion assays to evaluate metastatic potential, cisplatin sensitivity assays to study drug resistance, and RT-qPCR for target gene expression. These tools facilitate functional genomics screening and validation of HCFC1R1 as a therapeutic target. For further technical details, please contact Ascent Research.
